Results 81 to 90 of about 26,436 (212)
Background/Aims: At present, there are relatively few reports on the treatment consisting of transarterial chemoembolization (TACE) combined with lenvatinib, and there is no unified conclusion on the curative effect. The objective of this research was to
Daixin Li +7 more
core +1 more source
Prolonged duration of response in lenvatinib responders with thyroid cancer
, 2018 We present an updated analysis of lenvatinib in radioiodine-refractory differentiated thyroid cancer (RR-DTC) with new duration of response (DOR) data unavailable for the primary analysis. In this randomized, double-blind, multicenter, placebo-controlled
Mahadi Baig +4 more
core +1 more source
The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors
Medicinal Research Reviews, EarlyView.ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti +6 more
wiley +1 more source
Integrative characterization of human hepatocellular carcinoma‐derived organoids and their HBV‐associated biology [PDF]
Clin Transl Med20 HCC‐derived organoids, three adjacent non‐tumour tissue‐derived organoids, and 12 HCC‐derived cell lines from 20 patients were established and biobanked. Integrative analyses combining drug screening, whole‐exome sequencing, and RNA sequencing revealed molecular subtypes and identified candidate determinants of lenvatinib response.
Kim S +9 more
europepmc +2 more sources
Scientific ReportsLenvatinib is a multiple receptor tyrosine kinase inhibitor (TKI) approved for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). TKI are suspected of exacerbating muscle loss in patients with cancer.
Michael Praktiknjo +21 more
doaj +1 more source
, 2023 Hui Yang, Tiequan Yang, Guangpin Qiu, Jie Liu Department of Interventional Therapy, Ningbo NO.2 Hospital, Ningbo, Zhejiang, People’s Republic of ChinaCorrespondence: Hui Yang, Department of Interventional Therapy, Ningbo NO.2 Hospital, No. 41, Xibei Road,
Yang H, Qiu G, Liu J, Yang T
core
The Journal of Pathology, EarlyView.Abstract Fibroblast growth factor receptor 1 (FGFR1) amplification, a significant cancer alteration with both prognostic and therapeutic relevance, lacks a standardized definition. The relationship between FGFR1 copy number (CN) variations and tumour microenvironment (TME) characteristics also remains poorly understood.
Yike Gao +6 more
wiley +1 more source
VIEW, EarlyView.Hepatocellular carcinoma (HCC) is frequently resistant to targeted therapies. We identify protein phosphatase Mg2+/Mn2+‐dependent 1G (PPM1G) as a key phosphatase that stabilizes mesenchymal‐epithelial transition factor (MET) by inhibiting its ubiquitination, thereby sustaining protein kinase B (AKT) signaling and promoting Twist‐mediated epithelial ...
Weixun Wu +8 more
wiley +1 more source
VIEW, EarlyView.LINC00892 is lowly expressed in HCC. LINC00892 overexpression induces ribosomal stress via inhibiting SBDS, restrains EIF6 nuclear translocation and activates p53 pathway. LINC00892 overexpression and p53 activation jointly suppress HCC progression. High LINC00892 is associted with infiltration of CD8+ T cells, B cells and macrophages, and associated ...
Xu Zhang +6 more
wiley +1 more source
A Spotlight on Yolk‐sac Tumors: Molecular Pathology, Current Diagnostics, and Novel Therapeutics
Andrology, EarlyView.ABSTRACT Background Yolk‐sac tumors are an aggressive subtype of testicular cancer that significantly contribute to disease progression and therapy resistance, especially in adults. While testicular cancer generally has high cure rates with cisplatin‐based treatment, adult yolk‐sac tumors often appear as components of mixed tumors with poor response to
Evangelos Prokakis +3 more
wiley +1 more source